


Abstract

The present invention relates to novel compounds of the general formula



wherein

- 5 R^1 is hydrogen;
- R^2 is hydrogen, trifluoromethyl or lower alkyl;
- R^3 is hydrogen or amino; or
- R^1 and R^2 or R^3 and R^2 taken together are $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$;
- Z is pyrimidin-4-yl, pyridin-4-yl, pyridin-2-yl or phenyl;
- 10 R^4, R^5 are each independently hydrogen, lower alkyl, trifluoromethyl, halogen, lower alkoxy, nitrilo, amino, lower alkyl-amino, di-lower alkyl-amino, piperazinyl, morpholinyl, pyrrolidinyl, vinyl, C_3-C_6 cycloalkyl, C_3-C_6 cycloalkenyl, t-buthylethynyl, hydroxyalkylethynyl, phenylethynyl, naphthyl, thiophenyl, or
- 15 phenyl, which may be substituted by halogen, lower alkoxy, lower alkyl, trifluoromethyl or nitro, or a group $-\text{NH}(\text{CH}_2)_n\text{NR}^6\text{R}^7$, $-\text{N}(\text{CH}_3)(\text{CH}_2)_n\text{NR}^6\text{R}^7$, $-\text{NH}(\text{CH}_2)_n-$ morpholin-4-yl or $-\text{NH}(\text{CH}_2)_n\text{OH}$;
- n is 2-4
- 20 R^6 and R^7 are each independently hydrogen or lower alkyl, and to their pharmaceutically acceptable salts.

It has been found that the compounds of formula I possess a selective affinity to 5HT-6 receptors.

This Sheet Has Been Replaced

